Floatz logo

Valganciclovir

Nodal Marginal Zone B-Cell Lymphoma

City of Hope Medical CenterSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Nodal Marginal Zone B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
ETOPOSIDE
University of California, Davis
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Romidepsin
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionDormant
BB
Indicative ·
68 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
61 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →